Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Mutation Confers Anti-EGFR Resistance

September 14th 2012

A common mutation in NSCLC confers resistance to tyrosine kinase inhibitors and worsens survival, creating a need for an alternative approach to treating the subgroup of patients with the mutation.

Hint of Survival Benefit in NSCLC With Bavituximab Plus Docetaxel

September 13th 2012

Patients with advanced non-small cell lung cancer lived twice as long when they received an indirect angiogenesis inhibitor plus docetaxel instead of docetaxel alone.

Dr. Gandara on Patient Selection for Molecular Testing

September 12th 2012

Dr. David Gandara from the UC Davis Comprehensive Cancer Center on Patient Selection for Molecular Testing in Lung Cancer

Alimta Combination Fails Survival Objectives in Phase III Study

September 6th 2012

Eli Lilly announced that a combination regimen of their chemotherapy drug Alimta and Avastin failed to improve survival in late stage non-squamous non-small cell lung cancer.

Rash Signals Better Outcome for Erlotinib Therapy in NSCLC

September 5th 2012

Cutaneous rash is a common adverse event among patients with non-small cell lung cancer who receive erlotinib and may indicate that the patient will experience a significantly greater survival benefit.

Dr. Scagliotti on Targeted Therapies and Chemotherapy

August 31st 2012

Dr. Giorgio Scagliotti, from the University of Turin, San Luigi Hospital, on Combining Targeted Therapies With Chemotherapy for Lung Cancer Patients.

Dr. Langer Discusses Treating Locally Advanced NSCLC

August 29th 2012

Dr. Corey Langer, from the University of Pennsylvania, Abramson Cancer Center, Discusses Treating Locally Advanced Non-small Cell Lung Cancer.

5 ALK-Related Questions for D. Ross Camidge, MD, PhD and Fredika M. Robertson, PhD

August 27th 2012

Two leading researchers discuss the role of the ALK signaling pathway and development into new ALK-targeted anticancer therapies.

ALK Inhibitors: Moving Rapidly From Discovery to Clinical Approval and Beyond

August 27th 2012

There has been stunning progress as preclinical findings of the ALK gene in patients with lung cancer were rapidly translated into the availability of an FDA-approved therapeutic ALK inhibitor, crizotinib.

Dr. Camidge Discusses Resequencing Lung Cancer

August 23rd 2012

Dr. Ross Camidge, from the University of Colorado Cancer Center, Discusses Resequencing Lung Cancer

Beyond the Basics: Unique Markers May Assist in Morphologic Classification

August 21st 2012

The presence of specific molecular biomarkers may assist in determining the correct morphologic diagnosis of the particular cancer being examined.

Exploring Ways to Broaden the Reach of Molecular Tumor Testing

August 17th 2012

The development of targeted therapies for a variety of tumor types has highlighted a greater need for widespread molecular testing to determine which patients have the mutations that these therapies target.

Smokers More Likely to Recall Graphic Warning Labels

August 16th 2012

Smokers are better able to remember the printed health-risk warnings that appear in cigarette advertisements and labels when the messages include images.

Dr. Herbst Explores Molecular Testing in Lung Cancer

August 15th 2012

Dr. Roy S. Herbst, from Yale Cancer Center, Explores Molecular Testing in Lung Cancer

Ongoing Trials in Lung Cancer Focus on Combination Therapies

August 14th 2012

Research presented at the ASCO Annual Meeting in June included these two clinical trials in advanced, metastatic non-small cell lung cancer.

Combination of Aflibercept and Topotecan Shows Activity in Patients With Small Cell Lung Cancer

August 10th 2012

Aflibercept combined with topotecan achieved slightly higher rates of PFS and disease control in patients with platinum-refractory, extensive-stage small cell lung cancer, compared with topotecan alone.

Dr. Gandara Discusses Molecular Testing for NSCLC

August 9th 2012

Dr. David Gandara, from University of California, Davis Comprehensive Cancer Center, discusses using the multiplexing assay for patients with non-small cell lung cancer

Dr. Sandler on Immunotherapies to Treat Lung Cancer

August 2nd 2012

Dr. Alan Sandler from the Oregon Health & Science University Discusses Immunotherapies for Lung Cancer

TS Expression Explored in ALK-positive NSCLC

August 1st 2012

Expression levels of thymidylate synthase may help point the way to new treatment options for patients with ALK-positive NSCLC, including combination therapy.

Study Supports Feasibility of Routine Molecular Screening of NSCLC in Community Setting

July 25th 2012

New study reveals that widespread molecular screening of nonâ€“small cell lung cancer is feasible and can be performed outside of large academic medical centers.